Results 111 to 120 of about 326,443 (336)

The development of potential targets in the treatment of non-small cell lung cancer

Open Life Sciences, 2016
The oncogenic driver mutations have been found that not only have potential sensitivity to epidermal growth factor receptor but also can inhibit anaplastic lymphoma kinase tyrosine kinase; more and more interest has been evoked in discovering additional ...
Zhang Jimin, Lin Zhihui
doaj   +1 more source

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. [PDF]

, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang, Castrellon, A, Diéras, V, Ettl, J, Finn, RS, Gauthier, ER, Gelmon, KA, Harbeck, N, Iyer, S, Joy, AA, Lipatov, O, Lu, DR, Mori, A, Rugo, HS, Slamon, DJ   +14 more
core  

Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]

, 2017
Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia, DE IULIIS, Francesca, Lanza, Rosina, Salerno, Gerardo, Scarpa, Susanna, Taglieri, Ludovica   +5 more
core   +1 more source

Dual HER2 Blockade [PDF]

Breast Care, 2017
Christoph Thomssen, Nagi S. El Saghir, Prudence A. Francis, Jacek Jassem, Hope S. Rugo, Michael Untch   +5 more
openaire   +2 more sources

TRIM38 Suppresses Breast Cancer Progression via Modulating SQSTM1 Ubiquitination and Autophagic Flux

Advanced Science, EarlyView.
TRIM38, an E3 ubiquitin ligase, suppresses breast cancer progression by inhibiting proliferation, migration, and invasion. Downregulated in breast tumor, its loss correlates with poor prognosis. Mechanistically, TRIM38 mediates K63‐linked ubiquitination of SQSTM1/p62 at K420, disrupting SQSTM1‐LC3 interaction and blocking autophagic flux.
Shan Jiang, Lijuan Wang, Dianwen Han, Peng Su, Bing Chen, Wenjing Zhao, Tong Chen, Ning Zhang, Xiaolong Wang, Yiran Liang, Yaming Li, Chen Li, Xi Chen, Dan Luo, Qifeng Yang   +14 more
wiley   +1 more source

Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance

Molecular & Cellular Oncology, 2017
Insulin receptor substrate 4 (IRS4) belongs to a family of cytoplasmic docking proteins mediating signals from cell surface receptors to downstream effectors.
Gerjon J. Ikink, John Hilkens
doaj   +1 more source

Tumor detection and elimination by a targeted gallium corrole [PDF]

, 2009
Sulfonated gallium(III) corroles are intensely fluorescent macrocyclic compounds that spontaneously assemble with carrier proteins to undergo cell entry.
Agadjanian, Hasmik, Farkas, Daniel L., Gray, Harry B., Gross, Zeev, Hwang, Jae Youn, Ma, Jun, Mahammed, Atif, Medina-Kauwe, Lali K., Rentsendorj, Altan, Valluripalli, Vinod   +9 more
core   +3 more sources

Bacteriophage‐Mimetic DNA Origami Needle for Targeted Membrane Penetration and Cytosolic Cargo Delivery

Advanced Science, EarlyView.
We designed a synthetic DNA origami needle‐like structure inspired by bacteriophages for targeted drug delivery. Functionalized with trastuzumab antibodies, cholesterol, and dyes, it selectively targets SKBR3 cancer cells. A glutathione‐triggered dye payload enables controlled release, and delivery is verified using confocal microscopy and live cell ...
Anirban Samanta, Mette Galsgaard Malle, Emily Tsang, Marjan Omer, Mads K. Skaanning, Sarah Youssef, Jørgen Kjems, Kurt V. Gothelf   +7 more
wiley   +1 more source

A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ

OncoImmunology, 2018
Despite substantial clinical progress with targeted therapies, current antibody-based approaches have limited efficacy at controlling HER2/neu-positive breast cancers, especially in the absence of chemotherapies.
Hongtao Zhang, Lian Lam, Yasuhiro Nagai, Zhiqiang Zhu, Xi Chen, Mei Q. Ji, Mark I. Greene   +6 more
doaj   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source